Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Celebrex Has Similar Risk Profile to Other NSAIDs, Could Be Sold Over-The-Counter

XTALKS VITALS NEWS

NSAID

The results of the PRECISION study showed that Celebrex is as safe as the two other NSAIDs tested.

Share this!

November 16, 2016 | by Sarah Hand, M.Sc.

Over-the-counter (OTC) drugs often start out as prescription medications. If a prescription drug sees widespread use, and its side effects and safety profile are well characterized, the US Food and Drug Administration (FDA) may approve the drug’s conversion to OTC availability.

This approval, however, comes with a few stipulations: the drug must be deemed as safe for the broad population, and the drug must be offered at the lowest effective dose to minimize the risk of adverse events. Still, a prescription to OTC conversion can result in boosted sales for pharmaceutical companies.

Pfizer’s recently-completed PRECISION study aimed to compare the risk profile of its painkiller, Celebrex, with other nonsteroidal anti-inflammatory drugs (NSAIDs) including ibuprofen and naproxen. As NSAIDs are known to increase the risk of heart attack and stroke in patients taking prescription doses for long periods of time, the study coordinators were specifically looking to characterize any adverse cardiovascular effects associated with Celebrex.

The results of the PRECISION study showed that Celebrex is as safe as the two other NSAIDs tested. Just over two percent (2.3 percent) of patients taking Celebrex died as a result of a cardiovascular event, compared to 2.7 percent of ibuprofen patients, and 2.5 percent of those taking naproxen.



“NSAIDs are an important treatment option for millions of arthritis patients around the globe,” said Dr. Freda Lewis-Hall, chief medical officer and executive vice president of Pfizer Inc. “The results of the PRECISION study underscore the cardiovascular and gastrointestinal safety of Celebrex for the long-term treatment of chronic arthritic conditions.”

Celebrex was approved by the FDA 17 years ago, and has since been the subject of a number of clinical trials and safety studies. Based on its similar risk-benefit profile compared to other OTC NSAIDs, and it’s lack of liver toxicity compared to acetaminophen, Celebrex could be ripe for an OTC conversion.

In addition to providing consumers with another OTC pain medication, the potential future availability of Celebrex on the shelf would be a big win for payers. As OTC medications are not covered by insurance companies, they wouldn’t need to pay for this version of Celebrex.


Keywords: NSAID, OTC, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.